Adeona Senior Vice President Of Research & Development To Present At American College Of Nutrition Annual Meeting
ANN ARBOR, Mich., Nov. 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that George J. Brewer, M.D., the Company's Senior Vice President of Research & Development, will be a featured speaker at the 52nd Annual Meeting of the American College of Nutrition to be held in Morristown, New Jersey, on November 16-19, 2011. Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.
Dr. Brewer will moderate the "Important Developments with Trace Elements" symposium with Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine and an Adeona Scientific Advisory Board member. During this symposium, Dr. Brewer will discuss the role of zinc deficiency and copper toxicity on cognitive loss and their contributions to the current epidemic of Alzheimer's disease.
Adeona also announced that, Diana Pollock, M.D., Lead Principal Investigator of the Company's clinical study that evaluated reaZin ™ in Alzheimer's disease patients at Morton Plant Neuroscience Institute on the campus of Morton Plant Hospital, will present top-line results that demonstrated, on average, that the cognitive function (as measured by three standardized cognitive tests) of the Alzheimer's patients managed with reaZin remained relatively stable over six months, while the placebo group showed deterioration. In addition, Dr. Pollock will present the age-related subgroup analysis that showed dosing-compliant Alzheimer's patients age 70 and over demonstrated statistically significant improvements in two of the three cognitive scoring measurements in the reaZin treatment group compared to the placebo group. Adeona's product candidate, reaZin (zinc cysteine), is being developed as a medical food for the dietary management of zinc deficiency associated with Alzheimer's disease.
About the American College of Nutrition (ACN)The mission of the ACN is to improve the quality of nutrition care by enhancing nutrition education for physicians. An integral part of ACN's education activities is providing opportunities to fill in the gaps in the current medical school curriculum as well as ongoing post-graduate training. The goal of this training is to enhance nutrition and metabolism knowledge and to promote the application of such knowledge in clinical practice for the prevention and treatment of disease. For more information about ACN, please visit the website at www.americancollegeofnutrition.org. About Adeona Pharmaceuticals, Inc. Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com. This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the use of zinc as a potential dietary management for cognitive deficits in Alzheimer's patients, the limitations inherent in post-hoc interpretations of clinical study results and our intent to further commercialize development of reaZin as a medical food. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, our failure to successfully commercialize reaZin for the management of Alzheimer's disease, the failure of reaZin to be accepted for dietary management of Alzheimer's disease, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. SOURCE Adeona Pharmaceuticals, Inc.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.